Predictive value c-reactive protein assessment in women with arterial hypertension

Kardiologiya

Volumn 51, Issue 8, 2011, Pages 32-38

  Andrievskaja, E M ^a   Ivleva, A Y ^a   Minina, E S ^a   Lagutina, O E ^a  

^a President Management Department RF   (Russian Federation)

Author keywords

Cardiovascular disease; New cardiovascular risk models; Risk estimation; Risk factors

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; METHODOLOGY; MIDDLE AGED; MONITORING; MORTALITY; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; STANDARD;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PRESSURE DETERMINATION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 80555142993     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Stramba-Bdiale M., Fox K. M., Prion S. G et al. Cardio-vascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006;27:994-1005.
2. Mosca L., Appel L. J., Benjamin L. J. et al. Evidence based guidelience for cardiovascular disease prevention in women. Circulation 2004;109:672-693.
3. Cook N. R., Ridker P. M., Buring J. E. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-29.
4. Ridker P. M., Buring J. E., Shih J. et al. Prosvpective study of C-reactive protein and the risk of future cardiovascular events among apparently health women. Circulation 1998;98:731-733.
5. Tice JA., Browner W., Tracy R. P., Cummings S. R. The relation of C-reactive protein levels to total and cardiovascular mortality in older U. S. women. Am J Med 2003;114:199-205.
6. Van der Meer I. M., de Maat M. P., Kiliaan A. J. et al. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Stady. Arch Intern Med 2003;163:1323-1328.
7. Khot U. N., Khot M. B., Bajazer C. T. et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
8. Monteiro P. P. Gender influences on coronary disease. Eur Heart J 2005;26(Suppl):21721.
9. Ridker P. M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-1999.
10. Ridker P. M., Buring J. E., Rifai N., Cook N. R. Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women. The Reynolds Risk Score. JAMA 2007;297:611-619.
11. Risk for CHD according to TC H DL-C ratio in the PROCAM Study. Nutr Metab Cardiovasc Dis 1998;8:205-271.
12. Pearson T. A., Mensah G. A., Alexander R. W. et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practies. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
13. HeartScore Demonstrations at the ESC Stend. www.heartscore.org